Literature DB >> 20190788

Protein aggregation diseases: pathogenicity and therapeutic perspectives.

Adriano Aguzzi1, Tracy O'Connor.   

Abstract

A growing number of diseases seem to be associated with inappropriate deposition of protein aggregates. Some of these diseases--such as Alzheimer's disease and systemic amyloidoses--have been recognized for a long time. However, it is now clear that ordered aggregation of pathogenic proteins does not only occur in the extracellular space, but in the cytoplasm and nucleus as well, indicating that many other diseases may also qualify as amyloidoses. The common structural and pathogenic features of these diverse protein aggregation diseases is only now being fully understood, and may provide novel opportunities for overarching therapeutic approaches such as depleting the monomeric precursor protein, inhibiting aggregation, enhancing aggregate clearance or blocking common aggregation-induced cellular toxicity pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190788     DOI: 10.1038/nrd3050

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  165 in total

1.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

3.  Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Authors:  S Sinha; J P Anderson; R Barbour; G S Basi; R Caccavello; D Davis; M Doan; H F Dovey; N Frigon; J Hong; K Jacobson-Croak; N Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; J Tung; D Schenk; P Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; L McConlogue; V John
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

4.  Anchorless prion protein results in infectious amyloid disease without clinical scrapie.

Authors:  Bruce Chesebro; Matthew Trifilo; Richard Race; Kimberly Meade-White; Chao Teng; Rachel LaCasse; Lynne Raymond; Cynthia Favara; Gerald Baron; Suzette Priola; Byron Caughey; Eliezer Masliah; Michael Oldstone
Journal:  Science       Date:  2005-06-03       Impact factor: 47.728

5.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

Review 6.  Antiprion immunotherapy: to suppress or to stimulate?

Authors:  Adriano Aguzzi; Christina J Sigurdson
Journal:  Nat Rev Immunol       Date:  2004-09       Impact factor: 53.106

7.  Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity.

Authors:  Giuseppina Tesco; Young Ho Koh; Eugene L Kang; Andrew N Cameron; Shinjita Das; Miguel Sena-Esteves; Mikko Hiltunen; Shao-Hua Yang; Zhenyu Zhong; Yong Shen; James W Simpkins; Rudolph E Tanzi
Journal:  Neuron       Date:  2007-06-07       Impact factor: 17.173

8.  In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase.

Authors:  Shinobu Kitazume; Kazuhiro Nakagawa; Ritsuko Oka; Yuriko Tachida; Kazuko Ogawa; Yi Luo; Martin Citron; Hiroshi Shitara; Choji Taya; Hiromichi Yonekawa; James C Paulson; Eiji Miyoshi; Naoyuki Taniguchi; Yasuhiro Hashimoto
Journal:  J Biol Chem       Date:  2004-09-13       Impact factor: 5.157

Review 9.  Memapsin 2 (beta-secretase) inhibitors: drug development.

Authors:  Arun K Ghosh; Nagaswamy Kumaragurubaran; Ling Hong; Gerald Koelsh; Jordan Tang
Journal:  Curr Alzheimer Res       Date:  2008-04       Impact factor: 3.498

10.  Differential inhibition of prion propagation by enantiomers of quinacrine.

Authors:  Chongsuk Ryou; Giuseppe Legname; David Peretz; John C Craig; Michael A Baldwin; Stanley B Prusiner
Journal:  Lab Invest       Date:  2003-06       Impact factor: 5.662

View more
  215 in total

1.  Localization of HET-S to the cell periphery, not to [Het-s] aggregates, is associated with [Het-s]-HET-S toxicity.

Authors:  Vidhu Mathur; Carolin Seuring; Roland Riek; Sven J Saupe; Susan W Liebman
Journal:  Mol Cell Biol       Date:  2011-10-28       Impact factor: 4.272

Review 2.  Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases.

Authors:  Daniel W Neef; Alex M Jaeger; Dennis J Thiele
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

3.  Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands.

Authors:  Thomas E Finn; Andrea C Nunez; Margaret Sunde; Simon B Easterbrook-Smith
Journal:  J Biol Chem       Date:  2012-05-01       Impact factor: 5.157

4.  Effect of sequence variation on the mechanical response of amyloid fibrils probed by steered molecular dynamics simulation.

Authors:  Hlengisizwe Ndlovu; Alison E Ashcroft; Sheena E Radford; Sarah A Harris
Journal:  Biophys J       Date:  2012-02-07       Impact factor: 4.033

5.  Two-steps control of cellular prion physiology by the extracellular regulated kinase-1 (ERK1).

Authors:  Frédéric Checler
Journal:  Prion       Date:  2012 Jan-Mar       Impact factor: 3.931

Review 6.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

7.  Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors.

Authors:  Haitao You; Shigeki Tsutsui; Shahid Hameed; Thomas J Kannanayakal; Lina Chen; Peng Xia; Jordan D T Engbers; Stuart A Lipton; Peter K Stys; Gerald W Zamponi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

8.  Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide.

Authors:  Christine C Lee; Mark C Julian; Kathryn E Tiller; Fanling Meng; Sarah E DuConge; Rehana Akter; Daniel P Raleigh; Peter M Tessier
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

9.  Molecular mechanisms of protein aggregation from global fitting of kinetic models.

Authors:  Georg Meisl; Julius B Kirkegaard; Paolo Arosio; Thomas C T Michaels; Michele Vendruscolo; Christopher M Dobson; Sara Linse; Tuomas P J Knowles
Journal:  Nat Protoc       Date:  2016-01-07       Impact factor: 13.491

10.  Helices 2 and 3 are the initiation sites in the PrP(C) → PrP(SC) transition.

Authors:  Jie Chen; D Thirumalai
Journal:  Biochemistry       Date:  2012-12-31       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.